Latest News
Feature
Congress extends CHIP, funds opioid crisis response following temporary shutdown
Bill also addressed controversial Medicare payment panel.
Conference Coverage
Adjuvant chemo halves DFS events in upper-tract urothelial cancer
SAN FRANCISCO - Trial enrollment was stopped early, after a median follow-up of 19.3 months, because of efficacy of chemotherapy.
Conference Coverage
Adding docetaxel to hormone therapy for advanced prostate cancer nets QOL benefit
SAN FRANCISCO – Adding docetaxel to first-line long-term hormone therapy for advanced prostate cancer, whether metastatic or not, improves quality...
News
FDA approves abiraterone acetate for metastatic high-risk CSPC
The approval expands on the previous indication for use in combination with prednisone for treatment of metastatic castration-resistant prostate...
From the Journals
PAM50-based score identifies low-risk subset with node-positive early-stage breast cancer
About 37% of patients with a single positive lymph node and 15% of patients with two positive nodes were identified as low risk, with very...
Conference Coverage
Pembrolizumab nets durable responses in sorafenib-treated advanced HCC
With a median follow-up of 8.4 months, the overall response rate was 16.3% and the median duration of response was 8.2 months.
Conference Coverage
Atezolizumab-bevacizumab combo tops sunitinib as first-line therapy for RCC
With a median follow-up of 15 months, compared with sunitinib, the combination of atezolizumab and bevacizumab prolonged investigator-assessed...
Conference Coverage
New model predicts survival in atezolizumab-treated advanced urothelial carcinoma
The model contains six factors and predicts survival of patients given the immune checkpoint inhibitor atezolizumab in the postplatinum setting....
Feature
Decline in non-Hodgkin lymphoma deaths to continue in 2018
The estimated mortality is highest in Maine and West Virginia, lowest in Utah.
Feature
Three-drug combo delivers PFS for myeloma in OPTIMISMM trial
Celgene announced the phase 3 trial results, which investigators intend to present at future meetings.
Conference Coverage
Be alert for BAP1 mutations in hereditary melanomas
MIAMI – They’re rare genetic mutations that can make melanoma more aggressive and lethal, as well as signal of a potentially elevated risk for...